Phospho-NFAT5 (S1197) Antibody

What is NFAT5 and why is phosphorylation at S1197 significant?

NFAT5 (Nuclear Factor of Activated T-cells 5) is a member of the NFAT family of transcription factors that plays a central role in inducible gene transcription during immune responses and osmotic stress adaptation. Unlike other monomeric NFAT family members, NFAT5 exists as a homodimer and forms stable complexes with DNA elements .

Phosphorylation at S1197 is particularly significant because it regulates NFAT5 activity. Interestingly, research indicates that phosphorylation at this site can have inhibitory effects on NFAT5 nuclear localization during osmotic stress response . The S1197 residue is located in the NFAT5 transactivation domain, and mutation studies have shown that alanine substitution at this site reduces NFAT5 transcriptional activity under both isotonic and hypertonic conditions .

How does phosphorylation at S1197 affect NFAT5 cellular localization?

Phosphorylation of S1197 appears to have context-dependent effects on NFAT5 localization. In vascular smooth muscle cells (VSMCs) exposed to biomechanical stretch, mimicking S1197 phosphorylation through a serine-to-glutamic acid (S→E) mutation actually limited NFAT5c's entry into the nucleus . This suggests that phosphorylation at this site may serve as a negative regulatory mechanism for NFAT5 nuclear translocation in mechanically stressed cells.

This finding contrasts with the demonstration of regulation by direct phosphorylation at other sites, highlighting the complex interplay of post-translational modifications that control NFAT5 activity . The specific kinases responsible for S1197 phosphorylation may vary depending on the cellular context and stress condition.

What are the recommended applications for Phospho-NFAT5 (S1197) Antibody?

Phospho-NFAT5 (S1197) antibodies have been validated for several applications:

Optimal working dilutions should be determined experimentally by each investigator, as they may vary depending on tissue type and experimental conditions .

How can I validate the specificity of Phospho-NFAT5 (S1197) Antibody in my system?

To validate antibody specificity for phospho-NFAT5 (S1197), implement the following approach:

• Phosphatase treatment control: Split your sample and treat one portion with lambda phosphatase before Western blotting. The signal should disappear in the treated sample if the antibody is phospho-specific.

• NFAT5 knockdown validation: Use siRNA against NFAT5 (e.g., 5′-CCA GTT CCT ACA ATG ATA A-3′ as described in the literature) to confirm signal reduction .

• Phospho-mimetic mutants: Compare tissues/cells expressing wild-type NFAT5 versus S1197A (non-phosphorylatable) or S1197E (phospho-mimetic) mutants. This approach has been used successfully to study NFAT5 phosphorylation in vascular smooth muscle cells .

• Stimulus-responsive validation: Expose cells to conditions known to affect NFAT5 phosphorylation (hyperosmolar stress or biomechanical stretch) and confirm expected changes in signal intensity .

What are effective experimental protocols for studying dynamic NFAT5 S1197 phosphorylation?

For temporal studies of NFAT5 S1197 phosphorylation:

• Time-course experiments: Subject cells to hyperosmolar conditions (e.g., by adding NaCl or sorbitol to media) and collect samples at different time points (30 min, 1h, 2h, 4h, 8h, 24h).

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions at each time point to track phosphorylation status in different cellular compartments. Use histone H3 as a nuclear loading marker .

• Quantitative analysis: Perform Western blot analysis using both phospho-specific and total NFAT5 antibodies to calculate the phosphorylation ratio and normalize to appropriate loading controls.

• Immunofluorescence time-lapse: For real-time visualization of phosphorylation and translocation, use immunofluorescence with the phospho-specific antibody at various time points after stimulation.

• Kinase inhibition studies: Apply specific inhibitors such as SB239063 (p38 MAPK inhibitor) or dasatinib (c-Abl kinase inhibitor) to determine kinase involvement in S1197 phosphorylation under different stress conditions .

How should I distinguish between different NFAT5 isoforms when studying S1197 phosphorylation?

Distinguishing between NFAT5 isoforms requires careful experimental design:

• Isoform-specific PCR: First confirm which NFAT5 isoforms are expressed in your cell type using semi-quantitative PCR with isoform-specific primers. Research has shown that biomechanical stretch can induce expression of specific isoforms like NFAT5c .

• Molecular weight analysis: Different NFAT5 isoforms have distinct molecular weights (e.g., calculated molecular weight of 166kD for the full-length protein) . Use high-resolution SDS-PAGE to separate isoforms.

• Tagged constructs: For overexpression studies, use tagged constructs specific to different isoforms (e.g., DDK-tagged NFAT5c has been used successfully to study isoform localization) .

• Subcellular localization: Different isoforms may show distinct localization patterns. For example, NFAT5c shows specific nuclear translocation patterns in response to biomechanical stretch .

• Isoform-specific antibodies: When available, use antibodies that can distinguish between isoforms alongside the phospho-specific antibody.

What signaling pathways regulate NFAT5 S1197 phosphorylation?

The regulation of NFAT5 S1197 phosphorylation involves several signaling pathways:

• p38 MAPK pathway: Studies in human limbal epithelial cells (HLECs) have shown that NFAT5 induction and nuclear translocation under hyperosmolar stress is inhibited by SB239063, a p38 MAPK inhibitor . This suggests p38 MAPK may regulate S1197 phosphorylation status.

• c-Abl kinase pathway: Research in vascular smooth muscle cells has demonstrated that the protein kinase inhibitor dasatinib, which targets c-Abl kinases, interferes with NFAT5 nuclear accumulation under biomechanical stress . While this hasn't been directly linked to S1197 phosphorylation, it indicates c-Abl may be involved in NFAT5 phospho-regulation.

• JNK pathway: JNK activity has been reported to regulate phosphorylation and nuclear translocation of NFAT5 in mechanically stimulated cells .

• Other kinases: ERK1/2, p38 MAP kinase, and calcineurin have been investigated but do not appear to affect biomechanically triggered translocation of NFAT5 .

The specific kinases directly responsible for S1197 phosphorylation remain to be definitively identified, presenting an important area for future research .

How does NFAT5 S1197 phosphorylation status affect cellular responses to stress?

NFAT5 S1197 phosphorylation has profound effects on cellular stress responses:

• Osmotic stress adaptation: In hyperosmolar conditions, NFAT5 phosphorylation contributes to cell survival. Studies in human limbal epithelial cells show that 45% of cells survive even after 48 hours of hyperosmolar stress, but apoptosis increases markedly with NFAT5 suppression .

• Inflammatory cytokine production: Phosphorylated NFAT5 regulates specific cytokines during stress responses. Among inflammatory cytokines induced in hyperosmolar stress conditions, IL-1β and TNF-α levels were significantly reduced after inhibition of NFAT5 .

• Cell cycle regulation: NFAT5 knockdown in stretched vascular smooth muscle cells led to downregulation of gene sets controlling fundamental regulatory mechanisms, including transcription, translation, and cell cycle progression . This suggests phosphorylation status may influence NFAT5's role in cell proliferation.

• Interaction with other pathways: The interplay between NFAT5 and NF-κB is particularly important. Most cells undergo death upon dual inhibition of NF-κB and NFAT5, indicating cooperative roles in cell survival signaling .

What technical challenges exist in detecting low levels of phosphorylated NFAT5?

Detecting low levels of phosphorylated NFAT5 presents several challenges:

• Signal amplification strategies: For tissues with low expression, consider using signal amplification methods such as tyramide signal amplification (TSA) or quantum dots to enhance detection sensitivity.

• Sample enrichment techniques: Implement phosphoprotein enrichment protocols using phospho-protein purification kits before Western blotting to concentrate the target phosphoprotein.

• Optimizing antibody conditions: Careful titration of primary and secondary antibodies, extended incubation times (overnight at 4°C), and reduced washing stringency may improve detection of low-abundance phospho-proteins.

• Addressing phosphatase activity: Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) throughout sample preparation to prevent dephosphorylation.

• Background reduction: Use proper blocking agents (5% BSA rather than milk for phospho-epitopes) and appropriate negative controls to distinguish true signal from background.

• Alternative detection methods: Consider phospho-specific ELISA or proximity ligation assay (PLA) which may offer greater sensitivity than traditional Western blotting for detecting low-abundance phospho-proteins.

What are the emerging applications for Phospho-NFAT5 (S1197) Antibody in disease research?

The Phospho-NFAT5 (S1197) Antibody shows promise for investigating several disease contexts:

• Cardiovascular pathologies: Since NFAT5 regulates responses to biomechanical stress in vascular smooth muscle cells, its phosphorylation status may be relevant to hypertension and atherosclerosis research .

• Ocular surface disorders: NFAT5's role in hyperosmolar stressed human limbal epithelial cells suggests applications in dry eye disease research, where tear hyperosmolarity is a key pathological factor .

• Inflammatory diseases: Given that NFAT5 regulates inflammatory cytokines like IL-1β and TNF-α, studying its phosphorylation could provide insights into chronic inflammatory conditions .

• Kidney disorders: NFAT5's critical role in osmoadaptation makes it particularly relevant to kidney research, where cells are regularly exposed to varying osmotic environments .

• Cancer research: NFAT5's involvement in cell cycle regulation and proliferation suggests potential roles in cancer progression that could be explored through phosphorylation status assessment .

Future studies should focus on establishing direct connections between S1197 phosphorylation patterns and disease progression or therapeutic responses.

How can researchers design experiments to identify specific kinases that phosphorylate NFAT5 at S1197?

To identify kinases responsible for NFAT5 S1197 phosphorylation:

• Kinase inhibitor screening: Systematically test panels of kinase inhibitors (focusing on p38 MAPK, JNK, and c-Abl inhibitors based on current evidence) to identify candidates that reduce S1197 phosphorylation.

• In vitro kinase assays: Perform in vitro kinase assays with recombinant candidate kinases and NFAT5 substrate (wild-type and S1197A mutant) to confirm direct phosphorylation.

• Kinase knockdown/knockout: Use siRNA or CRISPR-Cas9 to deplete specific kinases and assess effects on S1197 phosphorylation during stress responses.

• Phosphoproteomic analysis: Implement large-scale phosphoproteomics to identify changes in NFAT5 phosphorylation sites under various conditions and after kinase manipulations.

• Computational prediction: Utilize kinase-specific phosphorylation site prediction algorithms to identify candidate kinases based on the sequence surrounding S1197.

• Proximity-based labeling: Apply BioID or APEX approaches with kinase baits to identify proteins that physically interact with NFAT5 during stress responses.

The identification of specific kinases responsible for S1197 phosphorylation remains an important knowledge gap in understanding NFAT5 regulation .

What are the optimal storage conditions for Phospho-NFAT5 (S1197) Antibody?

For optimal preservation of antibody activity:

• Long-term storage: Store at -20°C for up to one year in aliquots to minimize freeze-thaw cycles .

• Short-term storage: For frequent use, store at 4°C for up to one month .

• Formulation: Most commercial Phospho-NFAT5 (S1197) antibodies are provided in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to maintain stability .

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles as they can degrade antibody quality and reduce specificity .

• Working dilutions: Prepare working dilutions immediately before use and discard unused diluted antibody rather than storing it.